Validación de una escala para evaluación de síntomas colaterales extrapiramidales de Simpson-Angus
Validating the Simpson-Angus extra-pyramidal collateral symptom evaluation scale
Palabras clave:
Enfermedad de Parkinson Secundaria, escalas, valoración, psiquiátrica, agentes antipsicóticos, estudios, validación, estudio comparativo, examen neurológico (es)Secondary Parkinsons Disease, psychiatric status rating scale, antipsychotic agent, validation study, comparative study, neurological examination (en)
Descargas
Objetivos. Validar la Escala para Evaluación de Síntomas Colaterales Extrapiramidales de Simpson-Angus en Colombia, usando una versión en lengua española.
Métodos. Estudio de validación de escala de medición, que constó de cuatro fases: traducción de la escala, estudio piloto, aplicación preliminar para análisis factorial, y análisis de validez, confiabilidad y sensibilidad al cambio del instrumento.
Resultados. La estructura factorial y la consistencia interna se evaluaron en 86 pacientes psiquiátricos hospitalizados. La confiabilidad test-retest e intervaluador se analizaron en una submuestra de 15 pacientes. El análisis de la validez de criterio concurrente se efectuó aplicando de manera simultánea las escalas de Simpson-Angus y la escala de Chouinard. La sensibilidad al cambio fue evaluada comparando las puntuaciones en dos momentos clínicamente diferentes en una submuestra de 20 pacientes. El análisis de factores principales mostró que la escala corresponde a una estructura unidimensional y dentro de esa estructura el signo de la Glabela aporta poco a la variabilidad total de la condición medida por la Escala. Los valores de confiabilidad test-retest, confiabilidad interevaluador, validez de criterio concurrente y sensibilidad al cambio fueron satisfactorios, con valores de estimadores de correlación superiores a 0,8 y niveles de precisión satisfactorios.
Conclusiones. La versión española adoptada en este estudio tiene adecuadas propiedades de medición del síndrome extrapiramidal inducido por neurolépticos y puede considerarse un instrumento de utilidad tanto en la práctica clínica como en investigación en Colombia. Sin embargo, una limitación importante puede ser su deficiencia para detectar dominios diferentes de la rigidez.
Objectives. The study was aimed at validating the Simpson-Angus scale for neuroleptic-induced extrapyramidal syndrome in Colombia, using a Spanish version of the scale.
Methods. The scale was validated in four steps: translating the scale, pilot study, preliminary use for factorial analysis and analysis of validity, reliability and sensitivity to change.
Results. Factorial structure and internal consistency were evaluated in 86 psychiatric inpatients. Test-retest and inter-rater reliability were evaluated in a 15-patient subgroup. Concurrent validity was analysed by simultaneously applying Simpson-Angus and Chouinard scales. Sensitivity to change was evaluated by comparing the scores of two different clinical points in a 20-patient subgroup. Main factor analysis revealed that the scale has a one-dimensional structure; the Glabella tap did not contribute towards total variability of the condition measured for the scale. Test-retest and inter-rater reliability values, concurrent validity and sensitivity to change were good. Correlation estimation scores were above 0.8 and accuracy levels were also good.
Conclusions. The Spanish version of the SA scale, adapted for this study, is suitable for assessing neuroleptic-induced extrapyramidal syndrome; it would be a useful instrument in both clinical practice and research settings in Colombia. However, an important limitation could be its lack of detecting any domain different to that of rigidity.
Referencias
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington D.C.; 2000. p. 734-736, 791-807.
Miller AL, Chiles JA, Chiles JK, et al: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. Journal of Clinical Psychiatry 1999; 60:649-657.
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. American Journal of Psychiatry 1997; 154 (Apr suppl):1-63.
McEvoy J, Weiden P, Smith T, Carpenter D, Kahn D, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia. Journal of Clinical Psychiatry 1996; 57 (suppl 12B):1-58.
Barnes, Thomas. Clinical Assessment of the Extrapyramidal Side Effects of Antipsychotic Drugs. Journal of Psychopharmacology 1992; 6(2):214-221.
Mazure C, Cellar J, Bowers M, Nelson C, Takeshita J, Zigun B. Assessment of Extrapyramidal Sintoms During Acute Neuroleptic Treatment. Journal of Clinical Psychiatry 1995;56(3):94-100.
Chouinard G, Annable L, Ross-Chouinard A. Ethopropazine and Benztropine in Neuroleptic-induced Parkinsonism. Journal of Clinical Psychiatry 1979;40: 147-152.
Chouinard G, Ross-Chouinard A, Annable L, y Jones B. Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences 1980; 7:233-239.
Gerlach J, Korsgaard S, Clemmesen P, Lund A, Magelund G, Noring U, et al. The St. Hans Rating Scale for Extrapyramidal Syndromes: reliability and validity. Acta Psychiatrica Scandinavica 1993; 87:244-252.
Simpson G, Angus J. A Rating Scale for Extrapyramidal Side Effects. Acta Psychiatrica Scandinavica 1970; 212 (Supl 44): 11-19.
Streiner, David. A Checklist for Evaluating the Usefulness of Rating Scales. Canadian Journal of Psychiatry 1993; 38 (2):140-148.
Stanilla J, Simpson G. Treatment of Extrapyramidal Side Effects. En Schatzberg-Nemeroff: Textbook of Psychopharmacology. 2ª Edición. American Psychiatric Press, Inc. Washington; 1998. p: 349-352.
Norman GR, Streiner DL. Bioestadística. Barcelona: Mosby Doyma Libros; 1996.
Donner A, Eliasziw M. Sample size requirements for reliability studies. Statistics in Medicine 1987; 6:441-448
. 15. Sánchez R, Echeverry J. Validación de escalas de medición en salud. Rev Salud Publica, 2004 Sep-Dec;6 (3):302-18.
Steichen TJ. Concordance correlation coefficient. Stata Technical Bulletin 1998; STB43:35.39.
Lin L. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45:255-268.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; I: 307-310.
Glearson JR. Within subjects (repeated measures) ANOVA, including between subjects factors. Stata Technical Bulletin 1999; STB 47:40-45.
StataCorp. 2003. Stata Statistical Software: Release 8.0 College Station, TX: Stata Corporation.
Lejoyeux M, Gorwood P, Stalla-Bourdillon A, Adés J. Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms. Encephale. 1993 Jan-Feb; 19 (1):17-21.
Inada T, Beasley CM Jr, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003 Jan; 18 (1):39-48.
Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci 1993; 5:56-60.
Janno S, Holi MM, Tuisku K, Wahlbeck K.Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia. BMC Neurol. 2005; 5(1):5. [Internet] Disponible en: http://www.biomedcentral.com/1471-2377/5/5. Acceso: marzo de 2005.
Chan RC, Chen EY. Blink rate does matter: a study of blink rate, sustained attention, and neurological signs in schizophrenia. J Nerv Ment Dis. 2004 Nov; 192 (11):781-783
Taiminen T, Jaaskelainen S, Ilonen T, Meyer H, Karlsson H, Lauerma H, Leinonen KM, Wallenius E, Kaljonen A, Salokangas RK. Habituation of the blink reflex in first-episode schizophrenia, psychotic depression and non-psychotic depression. Schizophr Res. 2000 Jul 7; 44 (1):69-79.
Stevens JR. Eye blink and schizophrenia: psychosis or tardive dyskinesia? Am J Psychiatry. 1978 Feb; 135 (2):223-226.
Diederich N, Gotees C. Drug-induced Movement Disorders. Neurologic Clinics of North America 1998; 16 (1): 125-139.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Visitas a la página del resumen del artículo
Descargas
Licencia

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.
Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.








